Condition

AML clinical trials and research

• 41Clinical trials
• 1New in 30 days
• 7Countries

Newest AML clinical trials

All recruiting trials (41)

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• CRD3874-SI in People with Leukemia

  A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07661095

• Allogeneic CAR-T CT0890B for relapsed/refractory AML

  This study tests whether a universal CAR-T cell therapy called CT0890B is safe and potentially effective for adults with relapsed or refractory acute myeloid leukemia who express NKG2D ligands.

  Recruiting Phase 1 Peking University People's Hospital · Beijing · NCT07617285

• Biomarkers in Bone Marrow to Predict AML Chemosensitivity

  This study tests whether markers in bone marrow can predict how adults with AML will respond to chemotherapy.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07587944

• Azacitidine plus venetoclax maintenance vs azacitidine alone in AML

  This trial tests whether adding venetoclax to azacitidine maintenance helps people with AML stay disease-free after achieving first remission.

  Recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07539818

• Azacitidine with APG1252 in high-risk AML (Phase 1b/2)

  This study tests whether adding APG1252 to azacitidine is safe and helps some patients with high-risk AML feel better or respond to treatment.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07508982

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

  This trial tests a new induction combo (VAM) to see if it is safe and shows early signs of helping people with newly diagnosed AML who can receive intensive chemotherapy.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07490288

• CG009301 for adults with relapsed or treatment‑resistant blood cancers

  This trial will try a new drug called CG009301 to see if it's safe and helps adults whose leukemia or related blood cancers have come back or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 Cullgen (Shanghai),Inc · Nanchang and 2 other locations · NCT07347171

• Leptin as a marker of chemotherapy sensitivity in adult AML

  This study will test whether higher leptin levels in bone marrow predict poorer response to standard chemotherapy in adults with newly diagnosed AML.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07163728

• Donor-derived γδ T cell therapy for MRD-positive AML after stem-cell transplant

  This trial tests whether giving donor-derived γδ T cells can help adults with MRD-positive AML after an allogeneic stem-cell transplant.

  Recruiting Early Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Beijing · NCT07126782

• Long-term follow-up of TScan TCR-T therapies

  This follow-up will see if the TSC-100 and TSC-101 TCR-T therapies remain safe and continue to control disease over the long term in people who already received them.

  Recruiting at 2 sites TScan Therapeutics, Inc. · Duarte, California and 1 other locations · NCT06976736

• Compare two post-transplant drug combinations to prevent graft-versus-host disease

  This phase 2 trial will test whether giving ruxolitinib instead of mycophenolate mofetil, together with cyclophosphamide and sirolimus after a stem cell transplant, better prevents graft-versus-host disease in older adults with AML or related blood cancers.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06973668

• Using genetic information to guide maintenance therapy after stem cell transplantation for blood cancers

  This study is testing whether personalized treatment based on genetic information can help people with blood cancers like acute myeloid leukemia and myelodysplastic syndromes stay healthy after a stem cell transplant.

  Recruiting Phase 2/3 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06972641

• Conditioning regimens for elderly AML patients receiving haplo-HSCT

  This trial tests whether a fludarabine-based conditioning plan (Bu/Flu/Cy/ATG) reduces transplant-related mortality compared with a cyclophosphamide-based plan (Bu/Cy/ATG) in elderly AML patients getting haploidentical stem cell transplants.

  Recruiting Peking University People's Hospital · Beijing · NCT06946602

• New treatment for patients with relapsed acute myeloid leukemia

  This study is testing a new treatment called CER-1236 to see if it can help people with relapsed acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting at 5 sites Phase 1 CERo Therapeutics Holdings, Inc. · Sacramento, California and 4 other locations · NCT06834282

• Comparing standard-dose and intermediate-dose cytarabine for treating acute myeloid leukemia with RUNX1-RUNX1T1 fusion

  This study is testing if using a higher dose of cytarabine can help adults with acute myeloid leukemia who have a specific gene fusion feel better and achieve remission compared to the standard dose.

  Recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06744504

• Evaluating a new chemotherapy regimen for relapsed or refractory AML

  This study is testing a new combination of chemotherapy drugs to see if it can help people with acute myeloid leukemia that hasn't responded to other treatments.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing · NCT06741722

• Testing FD-001 for recurrent or refractory blood cancers

  This study is testing a new medication called FD-001 to see if it can help people with tough-to-treat blood cancers like acute myeloid leukemia and non-Hodgkin lymphoma.

  Recruiting Phase 1 Chengdu FenDi Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT06731699

• Ivosidenib maintenance after allogeneic stem cell transplant for IDH1‑mutant AML or high‑risk MDS

  This will test whether taking ivosidenib after a recent allogeneic stem cell transplant helps people with AML or high‑risk MDS who have an IDH1 mutation stay in remission longer.

  Recruiting at 14 sites Phase 2 Technische Universität Dresden · Aachen and 16 other locations · NCT06717958

• Venetoclax with ivosidenib and azacitidine for newly diagnosed AML with an IDH1 mutation

  This treatment tests whether combining venetoclax, ivosidenib, and azacitidine helps people newly diagnosed with AML that has an IDH1 mutation.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06611839

• Efficacy of a triple drug regimen for newly diagnosed AML patients with FLT3 mutation

  This study is testing a new combination of three drugs to see if it helps newly diagnosed acute myeloid leukemia patients with FLT3 mutations respond better to treatment.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06561880

• Intermediate-dose treatment for CEBPA double-mutated AML

  This study is testing a new intermediate-dose treatment for people with CEBPA double-mutated acute myeloid leukemia to see if it works better than the standard treatment.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06529250

• CAR-T cell therapy targeting CD33 and CD123 for treating acute myeloid leukemia

  This study is testing a new CAR-T cell therapy that targets specific markers in the blood to see if it can help people with acute myeloid leukemia who haven't responded to other treatments.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06420063

• Combination treatment for newly diagnosed acute myeloid leukemia

  This study is testing a new combination treatment for adults with newly diagnosed acute myeloid leukemia who can't have standard chemotherapy to see if it can help them safely and effectively.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06386302

• Combining revumenib with standard chemotherapy and targeted therapy for acute myeloid leukemia

  This study is testing a new treatment combining revumenib with standard chemotherapy and another targeted therapy to see if it helps newly diagnosed patients with a specific type of acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · New Haven, Connecticut and 1 other locations · NCT06313437

• Exploring new treatment options for refractory or relapsed acute myeloid leukemia

  This study is testing different treatment options for people with stubborn or returning acute myeloid leukemia to see which ones work best for them.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06265545

• Enhancing stem cell transplant for children with high-risk acute myeloid leukemia

  This study is testing a new way to improve stem cell transplants for children and young adults with high-risk acute myeloid leukemia by using half-matched family donors and special immune cells to make the treatment safer and more effective.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT06158828

• Combination therapy with Venetoclax and Decitabine for relapsed or refractory AML

  This study is testing a new combination treatment of Venetoclax and Decitabine to see if it can help people with newly diagnosed or returning acute myeloid leukemia feel better and achieve remission.

  Recruiting Phase 2 University Hospital Tuebingen · Tübingen, Baden-Wurttemberg · NCT06156579

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Infusion of selected stem cells to improve graft function in blood cancer patients

  This study is testing if infusing special stem cells can help blood cancer patients who have had problems with their stem cell transplant feel better and avoid complications.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT06047886

• Examining the safety of ziftomenib combinations for patients with relapsed acute myeloid leukemia

  This study is testing if combining ziftomenib with standard treatments can safely help people with relapsed acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting at 43 sites Phase 1 Kura Oncology, Inc. · Gilbert, Arizona and 44 other locations · NCT06001788

• Adaptive treatment for acute myeloid leukemia based on early results

  This study is testing a new treatment plan for people with untreated acute myeloid leukemia to see if adding a drug called selinexor helps those who still have cancer after two weeks of initial therapy.

  Recruiting Phase 2 Shanghai Tong Ren Hospital · Shanghai and 3 other locations · NCT05736978

• T cell receptor depletion for blood cancer treatment

  This study is testing a new way to treat blood cancers by using a special treatment before a stem cell transplant to see if it helps both kids and adults do better after the procedure.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05735717

• Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers

  This study is testing a new drug called Tagraxofusp to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 15 sites Phase 1 Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California and 30 other locations · NCT05476770

• Registry of patients who received oNKord® treatment

  This study is tracking patients with acute myeloid leukemia who have received oNKord® treatment to see how it affects their health over time.

  Recruiting at 2 sites Glycostem Therapeutics BV · Hanover and 1 other locations · NCT05290662

• Combining CC-486 and Venetoclax for treating Acute Myeloid Leukemia

  This study is testing if a new combination of two medications, CC-486 and venetoclax, can help people with relapsed or hard-to-treat Acute Myeloid Leukemia feel better and improve their treatment outcomes.

  Recruiting at 2 sites Phase 1 University of Colorado, Denver · Aurora, Colorado and 1 other locations · NCT05287568

• Protecting the heart during treatment for acute myeloid leukemia

  This study is testing if giving heart-protecting medications to people with acute myeloid leukemia who are being treated with daunorubicin can help prevent heart damage during their treatment.

  Recruiting Phase 2 University of Virginia · Charlottesville, Virginia · NCT04977180

• First-in-human use of JAB-8263 in adults with advanced solid and blood cancers

  This trial will try JAB-8263, a BET inhibitor pill, in adults with advanced solid tumors or blood cancers that have progressed after standard treatments.

  Recruiting Phase 1/2 Jacobio Pharmaceuticals Co., Ltd. · Tianjin, Tianjin Municipality · NCT04686682

• Cord blood transplant for children and young adults with blood cancers and disorders

  This study is testing a new treatment using chemotherapy followed by a cord blood transplant to see if it can help children and young adults with serious blood cancers and disorders who don't have a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT04644016

• Investigating genetic factors in childhood cancer

  This study is trying to find out if certain genes passed down in families can increase the risk of childhood cancer by looking at samples from kids who have had cancer and their relatives.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT03050268

Related topics

Quick answers

How many AML clinical trials are recruiting right now?

41, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in China (21 trials), United States (17 trials), Germany (3 trials), Switzerland (1 trial), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 11, Phase 2: 9, Phase 1/2: 6, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →